Guggenheim Downgrades Adicet Bio to Neutral, Announces $20 Price Target
Portfolio Pulse from richadhand@benzinga.com
Guggenheim analyst Michael Schmidt downgraded Adicet Bio (NASDAQ:ACET) from Buy to Neutral and announced a $20 price target.
June 27, 2023 | 2:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Adicet Bio (NASDAQ:ACET) has been downgraded from Buy to Neutral by Guggenheim analyst Michael Schmidt, with a $20 price target.
The downgrade from Buy to Neutral by Guggenheim analyst Michael Schmidt indicates a less optimistic outlook for Adicet Bio's stock performance in the short term. The $20 price target announcement may also put downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100